Literature DB >> 1642235

Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients.

E D Lustbader1, W R Williams, M L Bondy, S Strom, L C Strong.   

Abstract

This paper presents the analysis of familial cancer data collected in a hospital-based study of 159 childhood soft-tissue-sarcoma patients. Two different statistical models detected excess aggregation of cancer, which could be explained by a rare dominant gene. For each kindred, we estimated the probability of the observed cancer distribution under the dominant-gene model and identified 12 families that are the most likely to be segregating the gene. Two of those families have confirmed germ-line mutations in the p53 tumor-suppressor gene. The relative risk of affection for children who are gene carriers was estimated to be 100 times the background rate. Females were found to have a slightly higher age-specific penetrance, but maternal and paternal lineages made equal contributions to the evidence in favor of the dominant gene. The proband's histology, ethnicity, and age at diagnosis were evaluated to determine whether any of these altered the probability of affection in family members. Only embryonal rhabdomyosarcoma was found to be a significant covariate under the dominant-gene model. While molecular genetic studies of familial cancer will eventually provide answers to the questions of genetic heterogeneity, age- and site-specific penetrance, mutation rates, and gene frequency, information from statistical models is useful for setting priorities and defining hypotheses.

Entities:  

Mesh:

Year:  1992        PMID: 1642235      PMCID: PMC1682662     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  16 in total

1.  Adrenal-cell carcinoma and rhabdomyosarcoma occurring in father and daughter: "SBLA" syndrome?

Authors:  M J Tomlinson; J A Bullimore
Journal:  Br J Radiol       Date:  1987-01       Impact factor: 3.039

2.  Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome.

Authors:  F P Li; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1969-12       Impact factor: 13.506

3.  Regressive logistic models for familial disease and other binary traits.

Authors:  G E Bonney
Journal:  Biometrics       Date:  1986-09       Impact factor: 2.571

4.  Cancer in the families of children with soft tissue sarcoma.

Authors:  J M Birch; A L Hartley; V Blair; A M Kelsey; M Harris; M D Teare; P H Jones
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

5.  Tumor-specific loss of 11p15.5 alleles in del11p13 Wilms tumor and in familial adrenocortical carcinoma.

Authors:  I Henry; S Grandjouan; P Couillin; F Barichard; C Huerre-Jeanpierre; T Glaser; T Philip; G Lenoir; J L Chaussain; C Junien
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

6.  A germ line mutation in exon 5 of the p53 gene in an extended cancer family.

Authors:  J C Law; L C Strong; A Chidambaram; R E Ferrell
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

7.  A cancer family syndrome in twenty-four kindreds.

Authors:  F P Li; J F Fraumeni; J J Mulvihill; W A Blattner; M G Dreyfus; M A Tucker; R W Miller
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

8.  A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting.

Authors:  H Scrable; W Cavenee; F Ghavimi; M Lovell; K Morgan; C Sapienza
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

9.  Li-Fraumeni syndrome: a case report from Italy.

Authors:  M Orjuela; G Perilongo; G Basso; M Carli; L Zanesco
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

10.  Parental cancer in an unselected cohort of children with cancer referred to a single centre.

Authors:  E N Thompson; N S Dallimore; D L Brook
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

View more
  49 in total

1.  Individual-specific liability groups in genetic linkage, with applications to kindreds with Li-Fraumeni syndrome.

Authors:  Sanjay Shete; Christopher I Amos; Shih-Jen Hwang; Louise C Strong
Journal:  Am J Hum Genet       Date:  2002-01-30       Impact factor: 11.025

2.  Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.

Authors:  Phuong L Mai; Payal P Khincha; Jennifer T Loud; Rosamma M DeCastro; Renée C Bremer; June A Peters; Chia-Ying Liu; David A Bluemke; Ashkan A Malayeri; Sharon A Savage
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

3.  An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53.

Authors:  J M Varley; G McGown; M Thorncroft; K J Tricker; M D Teare; M F Santibanez-Koref; J Martin; J M Birch; D G Evans
Journal:  J Med Genet       Date:  1995-12       Impact factor: 6.318

4.  Timing and context: important considerations in the return of genetic results to research participants.

Authors:  Kate A McBride; Nina Hallowell; Martin H N Tattersall; Judy Kirk; Mandy L Ballinger; David M Thomas; Gillian Mitchell; Mary-Anne Young
Journal:  J Community Genet       Date:  2015-05-26

Review 5.  Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Authors:  Jonathan D Wasserman; Gerard P Zambetti; David Malkin
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

6.  p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy.

Authors:  R Schneider-Stock; K Radig; Y Oda; W Mellin; J Rys; A Niezabitowski; A Roessner
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

7.  Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome.

Authors:  Casey R Tak; Eman Biltaji; Wendy Kohlmann; Luke Maese; Pierre Hainaut; Anita Villani; David Malkin; Catherine M T Sherwin; Diana I Brixner; Joshua D Schiffman
Journal:  Pediatr Blood Cancer       Date:  2019-02-04       Impact factor: 3.167

8.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Authors:  Phuong L Mai; Ana F Best; June A Peters; Rosamma M DeCastro; Payal P Khincha; Jennifer T Loud; Renée C Bremer; Philip S Rosenberg; Sharon A Savage
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

9.  Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.

Authors:  Shenying Fang; Ralf Krahe; Guillermina Lozano; Younghun Han; Wei Chen; Sean M Post; Baili Zhang; Charmaine D Wilson; Linda L Bachinski; Louise C Strong; Christopher I Amos
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

10.  Impaired regulation of tumor suppressor p53 caused by mutations in the xeroderma pigmentosum DDB2 gene: mutual regulatory interactions between p48(DDB2) and p53.

Authors:  Toshiki Itoh; Cristin O'Shea; Stuart Linn
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.